WT1 vaccine
AssigneesThe Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
InventorsDavid B. Weiner, Jian Yan, Jewell Walters
Life of this patent
Estimating the term…
Abstract
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.
Claims18
An isolated nucleic acid molecule comprising one or more nucleic acid sequences selected from the group consisting of:
- SEQ ID NO:
- 1 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:1 without the leader sequence, a nucleic acid sequence that is at least 98% identical to SEQ ID NO:
- 1 over the entire length of SEQ ID NO:
- 1 without the leader sequence, a fragment comprising at least 90% of the entire length of a nucleic acid sequence that is at least 98% identical to SEQ ID NO:
- 1 over the entire length of SEQ ID NO:1 without the leader sequence, SEQ ID NO:
- 3 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:3 without the leader sequence, a nucleic acid sequence that is at least 98% identical to SEQ ID NO:3 over the entire length of SEQ ID NO:3 without the leader sequence, and a fragment comprising at least 90% of the entire length of a nucleic acid sequence that is at least 98% identical to SEQ ID NO:3 over the entire length of SEQ ID NO:3 without the leader sequence.
A method of treating an individual who has a WT1-expressing tumor or preventing development of a WT1-expressing tumor comprising administering an amount of a vaccine effective to slow growth of, reduce, or eliminate WT1-expressing tumors, wherein the vaccine comprises a nucleic acid molecule comprising one or more nucleic acid sequences encoding a protein or a fragment thereof, wherein the protein comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NO:2 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:
- 2 without the leader sequence, an amino acid sequence that is at least 98% identical to SEQ ID NO:2 over the entire length of SEQ ID NO:
- 2 without the leader sequence, a fragment comprising at least 90% of the entire length of an amino acid sequence that is at least 98% identical to SEQ ID NO:2 over the entire length of SEQ ID NO:
- 2 without the leader sequence, SEQ ID NO:4 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:4 without the leader sequence, an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 4 over the entire length of SEQ ID NO:
- 4 without the leader sequence, and a fragment comprising at least 90% of the entire length of an amino acid sequence that is at least 98% identical to SEQ ID NO:4 over the entire length of SEQ ID NO:
- 4 without the leader sequence.
A method of treating an individual who has a WT1-expressing tumor or preventing development of a WT1-expressing tumor comprising administering an amount of a vaccine effective to slow growth of, reduce, or eliminate WT1-expressing tumors, wherein the vaccine comprises a protein comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NO:2 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:2 without the leader sequence, an amino acid sequence that is at least 98% identical to SEQ ID NO:2 over the entire length of SEQ ID NO:
- 2 without the leader sequence, a fragment comprising at least 90% of the entire length of an amino acid sequence that is at least 98% identical to SEQ ID NO:2 over the entire length of SEQ ID NO:
- 2 without the leader sequence, SEQ ID NO:
- 4 without the leader sequence, a fragment comprising at least 90% of the entire length of SEQ ID NO:4 without the leader sequence, an amino acid sequence that is at least 98% identical to SEQ ID NO:4 over the entire length of SEQ ID NO:
- 4 without the leader sequence, and a fragment comprising at least 90% of the entire length of an amino acid sequence that is at least 98% identical to SEQ ID NO:4 over the entire length of SEQ ID NO:
- 4 without the leader sequence.
Dependencies are inferred from the claim text.